Pharmacological and clinical application of heparin progress: An essential drug for modern medicine

被引:87
作者
Qiu, Min [1 ]
Huang, Shengjie [1 ]
Luo, Chuanhong [1 ]
Wu, Zhenfeng [2 ]
Liang, Binzhu [1 ]
Huang, Haozhou [1 ]
Ci, Zhimin [1 ]
Zhang, Dingkun [1 ]
Han, Li [1 ]
Lin, Junzhi [3 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Pharm Sch, State Key Lab Southwestern Chinese Med Resources, Chengdu 611137, Peoples R China
[2] Jiangxi Univ Tradit Chinese Med, Minist Educ, Key Lab Modern Preparat TCM, Nanchang 330004, Jiangxi, Peoples R China
[3] Hosp Chengdu Univ Tradit Chinese Med, TCM Regulating Metab Dis Key Lab Sichuan Prov, Chengdu 610072, Peoples R China
关键词
Heparin; Related drugs; Pharmacology; Clinical application; Adverse reactions; MOLECULAR-WEIGHT HEPARIN; PERCUTANEOUS CORONARY INTERVENTION; INFLAMMATORY-BOWEL-DISEASE; FACTOR PATHWAY INHIBITOR; CRITICALLY-ILL PATIENTS; DEEP VENOUS THROMBOSIS; PROTEIN-C INHIBITOR; ACUTE LUNG INJURY; UNFRACTIONATED HEPARIN; NEBULIZED HEPARIN;
D O I
10.1016/j.biopha.2021.111561
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Heparin is the earliest and most widely used anticoagulant and antithrombotic drug that is still used in a variety of clinical indications. Since it was discovered in 1916, after more than a century of repeated exploration, heparin has not been replaced by other drugs, but a great progress has been made in its basic research and clinical application. Besides anticoagulant and antithrombotic effects, heparin also has antitumor, antiinflammatory, antiviral, and other pharmacological activities. It is widely used clinically in cardiovascular and cerebrovascular diseases, lung diseases, kidney diseases, cancer, etc., as the first anticoagulant medicine in COVID-19 exerts anticoagulant, anti-inflammatory and antiviral effects. At the same time, however, it also leads to a lot of adverse reactions, such as bleeding, thrombocytopenia, elevated transaminase, allergic reactions, and others. This article comprehensively reviews the modern research progress of heparin compounds; discusses the structure, preparation, and adverse reactions of heparin; emphasizes the pharmacological activity and clinical application of heparin; reveals the possible mechanism of the therapeutic effect of heparin in related clinical applications; provides evidence support for the clinical application of heparin; and hints on the significance of exploring the wider application fields of heparin.
引用
收藏
页数:17
相关论文
共 234 条
[1]   Clinical Experience with Bemiparin [J].
Abad Rico, Jose Ignacio ;
Lozano Sanchez, Francisco S. ;
Rocha, Eduardo .
DRUGS, 2010, 70 :25-33
[2]   Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[3]   Heparin induced thrombocytopenia: diagnosis and management update [J].
Ahmed, I. ;
Majeed, A. ;
Powell, R. .
POSTGRADUATE MEDICAL JOURNAL, 2007, 83 (983) :575-582
[4]   Coagulopathy and Plausible Benefits of Anticoagulation Among COVID-19 Patients [J].
Ahmed, Syed Imran ;
Khan, Shahzad .
CURRENT PROBLEMS IN CARDIOLOGY, 2020, 45 (09)
[5]   Effect of injection duration on bruising associated with subcutaneous heparin: A quasi-experimental within-subject design [J].
Akpinar, Reva Balci ;
Celebioglu, Ayda .
INTERNATIONAL JOURNAL OF NURSING STUDIES, 2008, 45 (06) :812-817
[6]   A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding [J].
Al-Horani, Rami A. ;
Abdelfadiel, Elsamani I. ;
Afosah, Daniel K. ;
Morla, Shravan ;
Sistla, Jyothi C. ;
Mohammed, Bassem ;
Martin, Erika J. ;
Sakagami, Masahiro ;
Brophy, Donald F. ;
Desai, Umesh R. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2019, 17 (12) :2110-2122
[7]   Heparin and insulin in the treatment of hypertriglyceridemia-induced severe acute pancreatitis [J].
Alagozlu, Hakan ;
Cindoruk, Mehmet ;
Karakan, Tarkan ;
Unal, Selahattin .
DIGESTIVE DISEASES AND SCIENCES, 2006, 51 (05) :931-933
[8]   Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models [J].
Alyahya, Reem ;
Sudha, Thangirala ;
Racz, Michael ;
Stain, Steven C. ;
Mousa, Shaker A. .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 46 (03) :1225-1231
[9]   Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study [J].
Angeloni, Giulia ;
Alberti, Silvia ;
Romagnoli, Enrico ;
Banzato, Alberto ;
Formichi, Marco ;
Cucchini, Umberto ;
Pengo, Vittorio .
INTERNAL AND EMERGENCY MEDICINE, 2011, 6 (02) :117-123
[10]  
[Anonymous], 2018, CHIN J FRONT MED SCI, V10, P1